ContraFect to Present at the “Exploring the Antibiotic Pipeline 2018” Symposium and also to Present New Data on CF-301 (exebacase) at IDWeek 2018 September 25, 2018
ContraFect Completes Enrollment in Phase 2 Clinical Trial Evaluating CF-301 (exebacase) in Patients with Staphylococcus Aureus Bacteremia September 6, 2018
ContraFect to Present at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance August 22, 2018
ContraFect to Participate in FDA Workshop on Development of Non-Traditional Therapies for Bacterial Infections August 14, 2018
